Lilly’s Reyvow (lasmiditan) Receives FDA’s Approval as the First Therapy in a New Class of Acute Treatment for Migraine

 Lilly’s Reyvow (lasmiditan) Receives FDA’s Approval as the First Therapy in a New Class of Acute Treatment for Migraine

Lilly’s Reyvow (lasmiditan) Receives FDA’s Approval as the First Therapy in a New Class of Acute Treatment for Migraine

Shots:

  • The US FDA approval is based on P-III SAMURAI and SPARTAN, evaluated the safety and efficacy of Reyvow vs PBO for the acute treatment of migraine in adults, resulted in meeting its 1EPs of pain freedom and freedom from most bothersome symptom
  • The Reyvow will be available in retail pharmacies following its recommended controlled substance classification, currently under review by DEA and is expected within 90 days of its FDA approval
  • Reyvow (lasmiditan) targets 5-HT1F receptors, first and only approved therapy in a new class of acute treatment for migraine, with/out aura in adults and will be available in oral doses of 50 mg, 100mg & 200mg               

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Pharmaceutical Technology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post